Auto-SummaryThe post argues that psilocybin will increase dreaming due to its interaction with serotonin receptors, particularly 5-HT-2, which decrease inhibitory mechanisms during REM sleep. Unlike LSD, psilocybin's auditory effects may lead to distinct dream characteristics. The author suggests a micro-dose may suffice, as serotonin activity is minimal during REM sleep, while higher doses are needed when awake. The post also explores potential lack of tolerance development and synergy with Calea, a plant inducing non-REM sleep dreams. Documentation supports the claims regarding serotonin activity during sleep cycles and LSD's impact on REM sleep.
OK you people asked for articles here they are.
Let me present my case and then put articles and quotes at the end. I had trouble finding direct documentation, so my case is roundabout. In presenting my case I address several things raised by posters. I would love to hear comments especially from those with experience on the science end of things.
First, Serotonin activity does not occur during REM sleep. Second, LSD will decrease inhibitory mechanisms that keep things from conscious awareness, through action on 5-HT-2 receptors Third, this LSD effect will increase dreaming Fourth, Psilocybin acts on those same reactors, albiet with more auditory effects. Conclusion, Psilocybin will increase dreaming.
That is all I have support for at the moment, but let me add some conjecture:
First, psilocybin has more auditory effects then LSD, so the dream characteristics are different. Second, a micro-dose is sufficient because during REM sleep, serotonin activity is nil. While awake and tripping, serotonin levels are high, so more psilocybin is needed. Third, you do not dream after a trip because hallucinations and dreams are so related. After tripping for several hours, your brain is 'dreamed out' as it were and may not be up for more of the neural activity that is responsible for both tripping and dreaming. Fourth, tolerance will not develop. Tolerance for mushrooms basically involves getting used to the psychedelic state. Since you are not entering a psychedelic state, you cannot get used to it, and tolerance will not develop. Fifth, this will not be synergistic with Calea. Calea inducing dreams during non-REM sleep. But during non-rem sleep there is serotonin activity. Since serotonin activity would drown out the effects of the micro-dose (?), no or little synergy will be present. However, synergy might be present in that dreams would be extended and of dirrening characteristics from the change between non-REM calea induced dreaming and REM+psilocybin dreaming. I currently have no Calea or money to obtain Calea, so I cannot test this unless I get money or someone donates to research  Here is some documentation for facts I state in my case.
http://www.antidepressantsfacts.com/pinealstory.htm
"One of the first significant discoveries about the serotonergic system in the brain was that it's activity was dramatically altered across the sleep-wake cycle. Serotonergic activity gradually decreases as one becomes drowsy and enter slow-wave sleep. An overall slowing of serotonergic activity is observed during slow-wave sleep known as non-REM sleep. During REM sleep (Rapid Eye Movement-the original dream sleep), serotonergic activity falls completely silent. Serotonergic activity returns to it's basic level several seconds prior to the end of REM sleep. REM sleep occurs in roughly 90-100 minute cycles, alternating with non-REM sleep (around 4 to 5 times during sleep). During non-REM sleep, there is lots of movement, but during REM sleep, only the eye muscles move. REM-dreaming turns on neurons in the medulla of the brainstem that inhibit all other motor activity. In this way it prevents the dreamer from sleepwalking and to act out his/her dreams in real time."
http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=3929 "The consistency and magnitude of the decrease of the latency of REM and dream incidence by LSD infusion warrent the assumption of a relationship between intracellurlar LSD increase and REM or Dream incidence."
"According to the mechanism described, LSD will temporarily decrease some inhibitory mechanisms responsible for keeping many cerebral processes from conscious awareness. This would result in dreaming during sleep and hallucinations during wakefullness The assumed connection between dreams, hallucinations, and memory storage and retrieval processes is further substantiated by LSD hallucinations being heavily loaded with old memories.."
http://www.erowid.org/chemicals/lsd/lsd_faq.shtml#mechanism Aghajanian embarked in 1980 upon a series of studies to evaluate how psychedelic drugs affect the locus coeruleus. He showed that any kind of sensory stimulation--sight, sound, smell, taste, or tactile sensation--speeds up the firing of locus coeruleus neurons in rats, and that the accelerated firing is greatly enhanced by treating the animals with LSD or mescaline. In contrast, nonpsychedelic drugs, such as amphetamines and antidepressants, fail to exert this effect. Moreover, the LSD analogue methysergide, which has no psychedelic effects in humans, is correspondingly ineffective in enhancing the reactivity of locus coeruleus neurons to sensory stimulation. Although psychedelic drugs increase the response of locus coeruleus cells to sensory stimulation, they do not cause the neurons to fire spontaneously in the absence of such stimulation. Moreover, directly applying LSD or mescaline to locus coeruleus neurons does not enhance the neurons' reponse to sensory stimulation. We must therefore conclude that the effect of psychedelic drugs on sensory stimulation is indirect--the drugs presumably interact with a different set of neurons that in turn make direct contact with the locus coeruleus. What is particularly fascinating about Aghajanian's findings is how nicely they correspond to what we know about the effects of psychedelic drugs in humans, and how readily they explain the way psychedelic drugs accentuate all our sensory perceptions.
http://www.maps.org/news-letters/v07n1/07112bea.html Psilocybin is an "agonist[ ] or partial agonist[ ] at several subtypes of the serotonin (5HT) receptor: 5HT-2, 5HT-1c, and 5HT-1a" (Strassman, 1992, p. 241), and the chemical structure of psilocybin's metabolite, psilocin, is close in structure to serotonin.
-------------------- "I am eternally free"
|